+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Narcolepsy Drugs Market by Disease Type and Therapeutics Type: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 4844575
  • Report
  • July 2019
  • Region: Global
  • 166 pages
  • Allied Analytics LLP
1 of 4
Narcolepsy is characterized by several symptoms that include cataplexy, excessive daytime sleepiness, hallucinations, and sleep paralysis. In addition, patients suffering from narcolepsy experience automatic behaviors such as eating, walking, or driving, in a dazed manner. Symptoms differ from patient to patient, and are diagnosed between the ages of 7 and 25. The global narcolepsy drugs market accounted for around $2,429 million in 2018, and is expected to reach $5,360 million by 2026, registering a CAGR of 10.3% from 2019 to 2026.

Although narcolepsy is a rare and underdiagnosed chronic condition, many cases have been reported of the people affected by this disease. It was estimated that more than 1 in 2,000 people in the U.S. were affected by narcolepsy in 2012. Increase in severity of the disease and rise in the number of people being affected by narcolepsy are some of the key driving factors of the market. Furthermore, the availability of reimbursement for FDA-approved prescription medicines is expected to fuel the demand for these drugs. However, lack of awareness regarding the diagnosis and treatment availability hinders the market growth. Conversely, increase in the number of programs by various organizations to spread awareness regarding the importance of early narcolepsy diagnosis is anticipated to offer lucrative opportunities for market expansion.

The global narcolepsy drugs market is segmented based on disease type, therapeutics type, and geography. Depending on disease type, the market is categorized into daytime extreme sleepiness, cataplexia, and others. By therapeutics type, it is segregated into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and others. Region wise, the market is examined across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc., Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc., Bioprojet, and Graymark Healthcare, Inc. have been provided in this report. Product launch and technological advancements are the few strategies adopted by the key players of the global narcolepsy drugs market.

KEY BENEFITS FOR STAKEHOLDERS
  • This report highlights the market dynamics to understand the global narcolepsy drugs market and capitalize on the prevailing opportunities.
  • Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
  • Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
  • Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.
KEY MARKET SEGMENTS

By Disease Type
o Daytime Extreme Sleepiness
o Cataplexia
o Others

By Therapeutics Type
o Central Nervous System Stimulants
o Tricyclic Antidepressants
o Sodium Oxybate
o Selective Serotonin Reuptake Inhibitor
o Others

By Region
o North America
  • U.S.
  • Canada
  • Mexico
o Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Rest of Europe
o Asia-Pacific
  • Australia
  • Japan
  • India
  • China
  • Rest of Asia-Pacific
o LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
KEY MARKET PLAYERS
  • Ligand Pharmaceuticals
  • Addrenex Pharmaceuticals
  • Shire Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Arena Pharmaceuticals
  • Jazz Pharmaceuticals Plc.
  • Bioprojet
  • Graymark Healthcare, Inc.
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Parent Market Overview
3.3. Key Forces Shaping Narcolepsy Drugs Market
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low bargaining power of buyers
3.3.3. Low threat of new entrants
3.3.4. Moderate threat of substitutes
3.3.5. Moderate intensity of rivalry
3.4. Pricing Analysis
3.4.1. Pricing Analysis, By Region, 2018 & 2025
3.5. Market Evolution
3.6. Value Chain Analysis
3.7. Impact of government regulations on global narcolepsy drugs market
3.8. Patent Analysis
3.8.1. By Region
3.8.2. By Applicant
3.9. Market Dynamics
3.9.1. Drivers
3.9.1.1. Increase in global prevalence of narcolepsy
3.9.1.2. Narcolepsy awareness programs and services
3.9.1.3. Presence of reimbursement policies regarding narcolepsy
3.9.2. Restraints
3.9.2.1. Adverse effects and risks related to narcolepsy drugs
3.9.2.2. Delayed diagnosis or misdiagnosis
3.9.3. Opportunity
3.9.3.1. Untapped markets in the developing countries

CHAPTER 4: NARCOLEPSY DRUGS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Daytime Extreme Sleepiness
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Cataplexia
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Other Disease Type
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country

CHAPTER 5: NARCOLEPSY DRUGS MARKET, BY THERAPEUTIC TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Central Nervous System Stimulants
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Tricyclic Antidepressants
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Sodium Oxybate
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Selective Serotonin Reuptake Inhibitor
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Other Therapeutic Type
5.6.1. Market size and forecast
5.6.2. Market analysis, by country

CHAPTER 6: NARCOLEPSY DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America market size and forecast, by disease type
6.2.3. North America market size and forecast, by therapeutic type
6.2.4. North America market size and forecast, by country
6.2.4.1. U.S. market size and forecast, by disease type
6.2.4.2. U.S. market size and forecast, by therapeutic type
6.2.4.3. Canada market size and forecast, by disease type
6.2.4.4. Canada market size and forecast, by therapeutic type
6.2.4.5. Mexico market size and forecast, by disease type
6.2.4.6. Mexico market size and forecast, by therapeutic type
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe market size and forecast, by disease type
6.3.3. Europe market size and forecast, by therapeutic type
6.3.4. Europe market size and forecast, by country
6.3.4.1. Germany market size and forecast, by disease type
6.3.4.2. Germany market size and forecast, by therapeutic type
6.3.4.3. France market size and forecast, by disease type
6.3.4.4. France market size and forecast, by therapeutic type
6.3.4.5. UK market size and forecast, by disease type
6.3.4.6. UK market size and forecast, by therapeutic type
6.3.4.7. Italy market size and forecast, by disease type
6.3.4.8. Italy market size and forecast, by therapeutic type
6.3.4.9. Spain market size and forecast, by disease type
6.3.4.10. Spain market size and forecast, by therapeutic type
6.3.4.11. Rest of Europe market size and forecast, by disease type
6.3.4.12. Rest of Europe market size and forecast, by therapeutic type
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific market size and forecast, by disease type
6.4.3. Asia-Pacific market size and forecast, by therapeutic type
6.4.4. Asia-Pacific market size and forecast, by country
6.4.4.1. Japan market size and forecast, by disease type
6.4.4.2. Japan market size and forecast, by therapeutic type
6.4.4.3. China market size and forecast, by disease type
6.4.4.4. China market size and forecast, by therapeutic type
6.4.4.5. Australia market size and forecast, by disease type
6.4.4.6. Australia market size and forecast, by therapeutic type
6.4.4.7. India market size and forecast, by disease type
6.4.4.8. India market size and forecast, by therapeutic type
6.4.4.9. South Korea market size and forecast, by disease type
6.4.4.10. South Korea market size and forecast, by therapeutic type
6.4.4.11. Rest of Asia-Pacific market size and forecast, by disease type
6.4.4.12. Rest of Asia-Pacific market size and forecast, by therapeutic type
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA market size and forecast, by disease type
6.5.3. LAMEA market size and forecast, by therapeutic type
6.5.4. LAMEA market size and forecast, by country
6.5.4.1. Brazil market size and forecast, by disease type
6.5.4.2. Brazil market size and forecast, by therapeutic type
6.5.4.3. Saudi market size and forecast, by disease type
6.5.4.4. Saudi market size and forecast, by therapeutic type
6.5.4.5. South Africa market size and forecast, by disease type
6.5.4.6. South Africa market size and forecast, by therapeutic type
6.5.4.7. Rest of LAMEA market size and forecast, by disease type
6.5.4.8. Rest of LAMEA market size and forecast, by therapeutic type

CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Market Share Analysis of Top Players, 2018 (%)
7.3. Product Mapping of Top Players
7.4. Competitive Heatmap

CHAPTER 8: COMPANY PROFILES
8.1. ARENA PHARMACEUTICAL, INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.2. BIOPROJET PHARMA SARL
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.3. JAZZ PHARMACEUTICAL PLC
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Operating segments
8.3.5. Business Performance
8.3.6. Key strategic moves and developments
8.4. LIGAND PHARMACEUTICALS INCORPORATED
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.5. NOVARTIS INTERNATIONAL AG
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. SHINOGI INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. TAKEDA PHARMACEUTICAL COMPANY
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
Note: Product cover images may vary from those shown
3 of 4
According to the report titled,'Narcolepsy Drugs Market by Type, Application, and Drug Formulation: Global Opportunity Analysis and Industry Forecast, 2019 - 2026,' the global narcolepsy drugs market generated $2,429 million in 2018, and is projected to reach $5,360 million by 2026, growing at a CAGR of 10.3% from 2019 to 2026. The electroencephalography devices segment accounted for more than one-fifth of the total market share in 2017.

Narcolepsy is a chronic disabling condition with symptoms such as cataplexy, excessive daytime sleepiness (EDS), sleep paralysis, hypnogogic hallucinations, and disrupted nocturnal sleep. Most of the narcolepsy drugs are used to treat symptoms related to cataplexy and excessive daytime sleepiness.

The global narcolepsy drug market size has witnessed significant growth in the past few years, owing to rise in awareness regarding the benefits of early diagnosis of narcolepsy drug and availability of wide variety of narcolepsy drugs contribute toward the market growth. Governments of countries such as India and South Africa are promoting the awareness of importance of narcolepsy, which is further expected to boost the narcolepsy drug market growth during the forecast period. However, stringent government regulations toward the approval for novel narcolepsy drugs is projected to hamper the market growth during the forecast period. Conversely, untapped markets in the developing countries are expected to offer remunerative opportunities for the market players in the near future.

Based on narcolepsy disease type, the narcolepsy drugs market is segmented into daytime extreme sleepiness, cataplexia, and others. Daytime extreme sleepiness segment is the highest revenue generator in the overall narcolepsy drugs market, as large number of people suffering from narcolepsy and other sleep disorders have a higher risk of this symptom, thus increasing the demand for narcolepsy drugs. However, the cataplexia segment is expected to grow at the highest rate, as patients suffering from cataplexia experience loss of muscle control, and almost 70% of narcolepsy patients are found to have this symptom.

Based on therapeutics type, the narcolepsy drugs market is segmented into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and others. The sodium oxybate segment held the highest share global narcolepsy drugs market in the 2018, as these drugs are highly effective to treat daytime extreme sleepiness and cataplexy. However, selective serotonin reuptake inhibitor segment is expected to grow at the highest rate due to increase in R&D activities for the development of these type of drugs by the key players.

Comprehensive competitive analysis and profiles of major market players such as Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc, Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc, Bioprojet, and Novartis have been provided in this report.

Key Findings of the Narcolepsy Drugs Market:

Based on disease type, the cataplexia segment is expected to experience rapid growth in the market, and is projected to grow at a highest CAGR from 2019 to 2026.
Depending on disease type, the daytime extreme sleepiness segment holds the highest share in 2018, and is anticipated to continue this trend during the forecast period.
By therapeutics type, the sodium oxybate segment was the major revenue contributor in 2018, and is anticipated to continue this trend during the forecast period.
Asia-Pacific region is anticipated to grow at high CAGR during the forecast period.
Note: Product cover images may vary from those shown
4 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll